Mylan Inc. shareholders voted Thursday to approve the company's pending acquisition of Abbott's non-U.S. developed markets specialty and branded generic business and reorganization in the Netherlands. Announced in July, the $5.3 billion all-stock transaction gives Abbott a 22 percent stake in Mylan and will move its generic business to a new company that will be headquartered in the tax-friendly Netherlands and called New Mylan.